Director, HTA, Value & Evidence (HV&E), I&I / Brepocitinib (Med Rheum)
Pfizer
12 hours ago
Remote friendly (New York, NY)
United States
Market Access
Role Responsibilities
- Develop and execute the global value and evidence generation strategy for Brepocitinib with the Brepocitinib HV&E team.
- Coordinate global and country team input on evidence needs; align and integrate into a coherent global evidence strategy across launch and lifecycle.
- Review, interpret, and translate clinical trial outputs (including CSRs) into HEOR-relevant insights, evidence gaps, and post-hoc analyses.
- Contribute to HV&E study design, execution, and oversight, including: cost-effectiveness and budget impact models; indirect treatment comparisons/network meta-analyses; systematic literature reviews; PROs/quality-of-life evidence; real-world evidence studies.
- Develop and maintain global value narratives and evidence deliverables (e.g., Global Value Dossiers) to support HTA submissions and payer decisions.
- Engage cross-functional clinical development teams to support rapid and broad access at launch.
- Collaborate with alliance partners on evidence strategy, roles, and execution; represent the HV&E team as needed.
- Build external partnerships with experts/HTA stakeholders/academics.
- Manage HV&E budgets and vendor relationships; ensure compliance with SOPs, governance, and regulatory requirements.
Basic Qualifications (Required)
- Graduate degree required (e.g., MSc, MPH, PhD).
- 7+ years with MSc/MPH/MBA; 5+ years with PharmD/PhD in HEOR or related fields.
- Deep knowledge of health services research methods: health economic modeling, cost-effectiveness/budget impact, indirect treatment comparisons, PROs/QoL, and RWE study design/analysis.
- Ability to manage multiple complex projects; influence in matrix/co-ownership environments.
- Strong English communication.
Preferred Qualifications
- Experience with HTA/reimbursement bodies (e.g., NICE, CADTH, ICER, PBAC).
- Experience supporting late-stage/launch assets; launch experience preferred.
- Inflammation & Immunology (incl. rheumatology) knowledge.
- Alliance/co-development experience.
Benefits (as stated)
- Base salary range: $176,600–$294,300; eligible for bonus (20% target) and share-based long-term incentive.
- 401(k) with matching; retirement contribution; paid vacation/holidays/personal days; caregiver/parental & medical leave; medical/dental/vision.
Application Instructions
- Last date to apply: April 29, 2026.
- Develop and execute the global value and evidence generation strategy for Brepocitinib with the Brepocitinib HV&E team.
- Coordinate global and country team input on evidence needs; align and integrate into a coherent global evidence strategy across launch and lifecycle.
- Review, interpret, and translate clinical trial outputs (including CSRs) into HEOR-relevant insights, evidence gaps, and post-hoc analyses.
- Contribute to HV&E study design, execution, and oversight, including: cost-effectiveness and budget impact models; indirect treatment comparisons/network meta-analyses; systematic literature reviews; PROs/quality-of-life evidence; real-world evidence studies.
- Develop and maintain global value narratives and evidence deliverables (e.g., Global Value Dossiers) to support HTA submissions and payer decisions.
- Engage cross-functional clinical development teams to support rapid and broad access at launch.
- Collaborate with alliance partners on evidence strategy, roles, and execution; represent the HV&E team as needed.
- Build external partnerships with experts/HTA stakeholders/academics.
- Manage HV&E budgets and vendor relationships; ensure compliance with SOPs, governance, and regulatory requirements.
Basic Qualifications (Required)
- Graduate degree required (e.g., MSc, MPH, PhD).
- 7+ years with MSc/MPH/MBA; 5+ years with PharmD/PhD in HEOR or related fields.
- Deep knowledge of health services research methods: health economic modeling, cost-effectiveness/budget impact, indirect treatment comparisons, PROs/QoL, and RWE study design/analysis.
- Ability to manage multiple complex projects; influence in matrix/co-ownership environments.
- Strong English communication.
Preferred Qualifications
- Experience with HTA/reimbursement bodies (e.g., NICE, CADTH, ICER, PBAC).
- Experience supporting late-stage/launch assets; launch experience preferred.
- Inflammation & Immunology (incl. rheumatology) knowledge.
- Alliance/co-development experience.
Benefits (as stated)
- Base salary range: $176,600–$294,300; eligible for bonus (20% target) and share-based long-term incentive.
- 401(k) with matching; retirement contribution; paid vacation/holidays/personal days; caregiver/parental & medical leave; medical/dental/vision.
Application Instructions
- Last date to apply: April 29, 2026.